Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Amyotrophic lateral sclerosis Clinical criteria: Treatment Phase: Initial treatment The condition must be diagnosed by a neurologist, AND Patient must not have had the disease for more than 5 years, AND Patient must have at least 60 percent of predicted forced vital capacity within the 2 months before commencing therapy with this drug, AND Patient must be ambulatory; OR Patient must not be ambulatory, and must be able to either use upper limbs or to swallow, AND Patient must not have undergone a tracheostomy, AND Patient must not have experienced respiratory failure. The date of diagnosis and the date and results of spirometry (in terms of percent of predicted forced vital capacity) must be supplied with the initial authority application.
“The mechanism of action of riluzole has not been completely elucidated but evidence to date suggests that it may involve inactivation of voltage dependent sodium channels and impairment of glutamatergic neurotransmission.”
“The elimination half-life ranges from 9 to 15 hours.”
“In humans, cytochrome P450 1A2 is the principal isozyme involved in N-hydroxylation. In vitro studies predict that CYP 2D6, CYP 2C19, CYP 3A4, and CYP2E1 are unlikely to contribute significantly to riluzole metabolism in humans.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.